| SB11 has been developed as a ranibizumab biosimilar and approved by the US Food and Drug Administration (FDA) and European Commission (EC). |
| SB11 demonstrated high similarity with reference products (EU/US-ranibizumab) in terms of structural, physicochemical, and biological properties. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.